For in vitro diagnostic use. Others Elecsys total P1NP IVD Elecsys® total P1NP CPS_000521 07027940190 Total P1NP Elecsys E2G 100 Elecsys total P1NP 04015630940288 Reagents, kits 100 tests cobas e 402/801 true 03141071190 Total P1NP Elecsys cobas e 100 Elecsys total P1NP 04015630919468 Reagents, kits 100 tests cobas e 411/601/602 true 07027940500 Elecsys total P1NP en 6 FF000000049FD40E FF0000000480600E 07027940190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of total P1NP in human serum and plasma.This assay is intended for use in monitoring therapy following the diagnosis of osteoporosisLREFFink E, Cormier C, Steinmetz P, et al. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 2000;11(4):295-303.,LREFGarnero P, Stevens RE, Ayres SA, et al. Short-term effects of new synthetic conjugated estrogens on biochemical markers of bone turnover. J Clin Pharmacol 2002;42(3):290-296.,LREFSharp CA, Evans SF, Risteli L, et al. Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older post-menopausal women. Eur J Clin Invest 1996;26:763-771. in post-menopausal women and in patients diagnosed with Paget’s disease of the bone.LREFAlvarez L, Guanabens N, Peris P, et al. Usefulness of biochemical markers of bone turnover in assessing response to treatment of Paget’s disease. Bone 2001;29(5):447-452.,LREFAlvarez L, RicOs C, Peris P, et al. Components of biological variation of biochemical parameters in Paget’s bone disease. Bone 2000;26(6):571-576.,LREFReid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone. Bone 2004;35:224-230.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en ms_03141071190 Elecsys total P1NP en 12 FF000000022D5A0E FF0000000003530E 03141071190 618 cobas e 411 2325 cobas e 602 623 MODULAR ANALYTICS E-MODULE 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of total P1NP in human serum and plasma.This assay is intended for use in monitoring therapy following the diagnosis of osteoporosisLREFFink E, Cormier C, Steinmetz P, et al. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 2000;11(4):295-303.,LREFGarnero P, Stevens RE, Ayres SA, et al. Short-term effects of new synthetic conjugated estrogens on biochemical markers of bone turnover. J Clin Pharmacol 2002;42(3):290-296.,LREFSharp CA, Evans SF, Risteli L, et al. Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older post-menopausal women. Eur J Clin Invest 1996;26:763-771. in post-menopausal women and in patients diagnosed with Paget’s disease of the bone.LREFAlvarez L, Guanabens N, Peris P, et al. Usefulness of biochemical markers of bone turnover in assessing response to treatment of Paget’s disease. Bone 2001;29(5):447-452.,LREFAlvarez L, RicOs C, Peris P, et al. Components of biological variation of biochemical parameters in Paget’s bone disease. Bone 2000;26(6):571-576.,LREFReid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone. Bone 2004;35:224-230.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 03141071500 Elecsys total P1NP en 14 FF00000004588A0E FF0000000034580E 03141071190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of total P1NP in human serum and plasma.This assay is intended for use in monitoring therapy following the diagnosis of osteoporosisLREFFink E, Cormier C, Steinmetz P, et al. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 2000;11(4):295-303.,LREFGarnero P, Stevens RE, Ayres SA, et al. Short-term effects of new synthetic conjugated estrogens on biochemical markers of bone turnover. J Clin Pharmacol 2002;42(3):290-296.,LREFSharp CA, Evans SF, Risteli L, et al. Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older post-menopausal women. Eur J Clin Invest 1996;26:763-771. in post-menopausal women and in patients diagnosed with Paget’s disease of the bone.LREFAlvarez L, Guanabens N, Peris P, et al. Usefulness of biochemical markers of bone turnover in assessing response to treatment of Paget’s disease. Bone 2001;29(5):447-452.,LREFAlvarez L, RicOs C, Peris P, et al. Components of biological variation of biochemical parameters in Paget’s bone disease. Bone 2000;26(6):571-576.,LREFReid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone. Bone 2004;35:224-230.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en